Foghorn Therapeutics Inc. Overview
Pro stress-test →Foghorn Therapeutics pioneers a new class of medicines that treat serious disease by correcting abnormal gene expression, targeting disease dependencies within the chromatin regulatory system to change how genes turn on and off. The company's therapies have potential to be the next wave of medicines for cancer and other diseases.
Strategic Profile
Pro stress-test →The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. Foghorn has a collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company operates in the precision therapeutics space targeting multiple cancer indications with its chromatin-targeting approach.
Competitive Landscape
Pro stress-test →Foghorn competes with other chromatin-targeting and epigenetic therapy companies in the oncology space. Key competitors include C4 Therapeutics, Kymera Therapeutics, and other synthetic lethal/chromatin regulation focused biotech firms. Foghorn differentiates through its proprietary Gene Traffic Control platform and collaborative partnership with Eli Lilly.
Industry Context
Foghorn Therapeutics Inc. operates in Precision Therapeutics / Oncology Biotechnology.
Key facts
Founded: 2015 · Headquarters: Cambridge, Massachusetts · Employees: 112 · Revenue: $7M (last quarter) · Market cap: $281.6M - $335.7M